OTC NSAID Labeling Could Be In For Changes Following Advisory Panel Vote
This article was originally published in The Tan Sheet
Executive Summary
Certain over-the-counter NSAIDs could be required to carry warnings regarding long-term heart risk resulting from chronic use following an FDA advisory committee vote
You may also be interested in...
Requested OTC NSAID Labeling Includes Cardiac Risk, Front Panel Changes
Manufacturers of over-the-counter non-steroidal anti-inflammatory drugs should prominently identify their products as NSAIDs on packaging, according to an FDA request
Requested OTC NSAID Labeling Includes Cardiac Risk, Front Panel Changes
Manufacturers of over-the-counter non-steroidal anti-inflammatory drugs should prominently identify their products as NSAIDs on packaging, according to an FDA request
Requested OTC NSAID Labeling Includes Cardiac Risk, Front Panel Changes
Manufacturers of over-the-counter non-steroidal anti-inflammatory drugs should prominently identify their products as NSAIDs on packaging, according to an FDA request